The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), a near-complete (≥90%) stabiliser of Transthyretin (TTR). It is approved for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalisation. The FDA approval is based on the ATTRibute-CM Phase III study, where Attruby significantly reduced […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!